AUD 0.09
(-2.17%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 | 400.22 Thousand AUD | 0.0% |
2023 | 896.79 Thousand AUD | 0.0% |
2022 | - AUD | 0.0% |
2021 | - AUD | -100.0% |
2020 | 300 Thousand AUD | 0.0% |
2019 | - AUD | -100.0% |
2018 | 500 Thousand AUD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 FY | 400.22 Thousand AUD | -55.37% |
2024 Q1 | 1.13 Million AUD | 0.0% |
2024 Q3 | 400.22 Thousand AUD | 13.11% |
2024 Q4 | 400.22 Thousand AUD | 0.0% |
2024 Q2 | 353.82 Thousand AUD | 0.0% |
2023 Q3 | 896.79 Thousand AUD | 0.0% |
2023 FY | 896.79 Thousand AUD | 0.0% |
2023 Q4 | 896.79 Thousand AUD | 0.0% |
2023 Q1 | - AUD | 0.0% |
2023 Q2 | - AUD | 0.0% |
2022 Q1 | - AUD | 0.0% |
2022 FY | - AUD | 0.0% |
2022 Q4 | - AUD | 0.0% |
2022 Q3 | - AUD | 0.0% |
2022 Q2 | - AUD | 0.0% |
2021 Q3 | - AUD | 0.0% |
2021 Q2 | - AUD | 0.0% |
2021 Q1 | - AUD | -100.0% |
2021 FY | - AUD | -100.0% |
2021 Q4 | - AUD | 0.0% |
2020 FY | 300 Thousand AUD | 0.0% |
2020 Q4 | 300 Thousand AUD | 0.0% |
2020 Q3 | 300 Thousand AUD | 0.0% |
2020 Q1 | - AUD | 0.0% |
2019 FY | - AUD | -100.0% |
2018 FY | 500 Thousand AUD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Australian Clinical Labs Limited | 55.06 Million AUD | 99.273% |
Genetic Signatures Limited | - AUD | -Infinity% |
Genetic Technologies Limited | - AUD | -Infinity% |
Healius Limited | 420.8 Million AUD | 99.905% |
Imagion Biosystems Limited | 750 Thousand AUD | 46.637% |
Integral Diagnostics Limited | 219.75 Million AUD | 99.818% |
INOVIQ Ltd | - AUD | -Infinity% |
Microba Life Sciences Limited | - AUD | -Infinity% |
Monash IVF Group Limited | 59.56 Million AUD | 99.328% |
Rhythm Biosciences Limited | - AUD | -Infinity% |
Sonic Healthcare Limited | 2.69 Billion AUD | 99.985% |